August 8, 2012
Joining Forces with Locus Development
Genomic Health Announces Second Quarter 2012 Financial Results and Business Progress - Product Revenue Increased 13% Compared with Prior Year - - Delivered Net Income of $1.8 Million - - Began Offering Oncotype DX® Colon Cancer Test for Stage III Patients - - Combined Invitae with Locus Development to Create Independent Genetics Company - - Conference Call Today at 4:30 p.m. ET - REDWOOD CITY, Calif., Aug. 8, 2012 /PRNewswire/ – Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended June 30, 2012. EXCERPT FROM PRESS RELEASE REGARDING INVITAE ONLY: Update on Invitae: “As the Invitae business strategy has evolved, we recognized an increasing distinction from our core business in cancer and, at the same time, identified meaningful synergies with Locus Development, a privately held company we have been investors in since 2011. We have concluded that the best path forward is to support the combination
Read more
February 6, 2012
Company Formation
Genomic Health Announces Formation of New Genetics Subsidiary REDWOOD CITY, Calif., Feb. 6, 2012 /PRNewswire/ – Genomic Health, Inc. (Nasdaq: GHDX) today announced plans to establish a wholly owned subsidiary with the goal of improving the quality of diagnosis, communication and support for millions of patients and their families faced with common and rare genetic conditions. The subsidiary is expected to be established by March 1, 2012 and provide its first commercial service in 2013. The new venture will be led by Randy Scott, who in his role as Executive Chairman for the past three years has focused on commercial applications of next generation sequencing. The new subsidiary will focus on accelerating the integration of the human genome into medical practice with an emphasis on bioinformatics and clinical utility. Dr. Scott will be CEO of the new subsidiary and remain a Genomic Health Board member and Kim Popovits,
Read more